Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)

Key facts

Sponsor

St. Anna Kinderkrebsforschung

Principal Investigator

Holger Lode, MD, PhD, M.D

University Medicine Greifswald

Intervention

ch14.18/CHO(drug)

Enrollment

288 target

Eligibility

1-21 years · All sexes

Timeline

2012 – 2020

Study locations (14)

• St. Anna Kinderspital, Vienna, Austria
• Institut Curie, Paris, France
• Institut Gustave Roussy, Villejuif, France
• University Children's Hospital, Greifswald, Germany
• Schneider Children's Medical Centre of Israel, Petach Tikvah, Israel
• Gaslini Children's Hospital, Genova, Italy
• Hospital Universitario La Fe, Valencia, Spain
• Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom
• University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
• Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
• Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
• University College Hospitals NHS Foundation Trust, London, United Kingdom
• Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
• The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom

Collaborators

University Medicine Greifswald · St. Anna Children's Hospital, Vienna · Hospital Universitario La Fe · Istituto Giannina Gaslini · Gustave Roussy, Cancer Campus, Grand Paris · Schneider Children's Medical Center, Israel · Great Ormond Street Hospital for Children NHS Foundation Trust · University Hospital, Toulouse · Johann Wolfgang Goethe University Hospital · Jena University Hospital · Children's University Hospital, Ireland · University Hospital Tuebingen · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Alder Hey Children's NHS Foundation Trust · University Hospitals Bristol and Weston NHS Foundation Trust · Newcastle-upon-Tyne Hospitals NHS Trust · The Leeds Teaching Hospitals NHS Trust · NHS Greater Glasgow and Clyde · Medical University of Graz · Medical University Innsbruck · Centre Leon Berard · Hospital Infantil Universitario Niño Jesús, Madrid, Spain · University Hospital Southampton NHS Foundation Trust · Institut Curie · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT07549321
  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
  Renaissance Pharma Ltd.
• RECRUITINGPHASE1, PHASE2NCT06625190
  Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
  University of Florida
• RECRUITINGPHASE1NCT07172958
  Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
  Children's National Research Institute
• RECRUITINGPHASE2NCT07085338
  A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
  St. Jude Children's Research Hospital
• RECRUITINGPHASE1, PHASE2NCT07399821
  An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
  Princess Maxima Center for Pediatric Oncology
• RECRUITINGPHASE1NCT06995872
  Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT06814496
  Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
  University of Arizona
• RECRUITINGPHASE1NCT07087002
  GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
  Stanford University

See all trials for Neuroblastoma →